Home >> Research Area >>Natural Products>>Diterpenoids>> Methyl 7,15-dihydroxydehydroabietate

Methyl 7,15-dihydroxydehydroabietate

CAS# 155205-65-5

Methyl 7,15-dihydroxydehydroabietate

Catalog No. BCN1693----Order now to get a substantial discount!

Product Name & Size Price Stock
Methyl 7,15-dihydroxydehydroabietate: 5mg $886 In Stock
Methyl 7,15-dihydroxydehydroabietate: 10mg Please Inquire In Stock
Methyl 7,15-dihydroxydehydroabietate: 20mg Please Inquire Please Inquire
Methyl 7,15-dihydroxydehydroabietate: 50mg Please Inquire Please Inquire
Methyl 7,15-dihydroxydehydroabietate: 100mg Please Inquire Please Inquire
Methyl 7,15-dihydroxydehydroabietate: 200mg Please Inquire Please Inquire
Methyl 7,15-dihydroxydehydroabietate: 500mg Please Inquire Please Inquire
Methyl 7,15-dihydroxydehydroabietate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Methyl 7,15-dihydroxydehydroabietate

Number of papers citing our products

Chemical structure

Methyl 7,15-dihydroxydehydroabietate

3D structure

Chemical Properties of Methyl 7,15-dihydroxydehydroabietate

Cas No. 155205-65-5 SDF Download SDF
PubChem ID 91895316 Appearance Powder
Formula C21H30O4 M.Wt 346.5
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name methyl (1R,4aS,9R,10aR)-9-hydroxy-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate
SMILES CC12CCCC(C1CC(C3=C2C=CC(=C3)C(C)(C)O)O)(C)C(=O)OC
Standard InChIKey MRTXWRPVFGYIEY-DEPWHIHDSA-N
Standard InChI InChI=1S/C21H30O4/c1-19(2,24)13-7-8-15-14(11-13)16(22)12-17-20(15,3)9-6-10-21(17,4)18(23)25-5/h7-8,11,16-17,22,24H,6,9-10,12H2,1-5H3/t16-,17-,20-,21-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Methyl 7,15-dihydroxydehydroabietate

The barks of Pinus yunnanensis

Methyl 7,15-dihydroxydehydroabietate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Methyl 7,15-dihydroxydehydroabietate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Methyl 7,15-dihydroxydehydroabietate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.886 mL 14.43 mL 28.86 mL 57.7201 mL 72.1501 mL
5 mM 0.5772 mL 2.886 mL 5.772 mL 11.544 mL 14.43 mL
10 mM 0.2886 mL 1.443 mL 2.886 mL 5.772 mL 7.215 mL
50 mM 0.0577 mL 0.2886 mL 0.5772 mL 1.1544 mL 1.443 mL
100 mM 0.0289 mL 0.1443 mL 0.2886 mL 0.5772 mL 0.7215 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Methyl 7,15-dihydroxydehydroabietate

Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin.[Pubmed:28347251]

Tumour Biol. 2017 Mar;39(3):1010428317694307.

The methyl methanesulfonate and ultraviolet-sensitive gene clone 81 protein is a structure-specific nuclease that plays important roles in DNA replication and repair. Knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 has been found to sensitize cancer cells to chemotherapy. However, the underlying molecular mechanism is not well understood. We found that methyl methanesulfonate and ultraviolet-sensitive gene clone 81 was upregulated and the ATM/Chk2 pathway was activated at the same time when MCF-7 cells were treated with cisplatin. By using lentivirus targeting methyl methanesulfonate and ultraviolet-sensitive gene clone 81 gene, we showed that knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 enhanced cell apoptosis and inhibited cell proliferation in MCF-7 cells under cisplatin treatment. Abrogation of ATM/Chk2 pathway inhibited cell viability in MCF-7 cells in response to cisplatin. Importantly, we revealed that ATM/Chk2 was required for the upregulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81, and knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 resulted in inactivation of ATM/Chk2 pathway in response to cisplatin. Meanwhile, knockdown of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 activated the p53/Bcl-2 pathway in response to cisplatin. These data suggest that the ATM/Chk2 may promote the repair of DNA damage caused by cisplatin by sustaining methyl methanesulfonate and ultraviolet-sensitive gene clone 81, and the double-strand breaks generated by methyl methanesulfonate and ultraviolet-sensitive gene clone 81 may activate the ATM/Chk2 pathway in turn, which provide a novel mechanism of how methyl methanesulfonate and ultraviolet-sensitive gene clone 81 modulates DNA damage response and repair.

Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexah ydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methano ne (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.[Pubmed:28368581]

J Med Chem. 2017 Apr 27;60(8):3405-3421.

The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectivity for GR leads to unwanted side effects in some patients. Optimization of the previously described fused azadecalin series of selective GR antagonists led to the identification of CORT125134, which is currently being evaluated in a phase 2 clinical study in patients with Cushing's syndrome.

Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.[Pubmed:28285912]

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1750-1753.

In an effort to discover potent camptothecin-derived antitumor agents, novel camptothecin analogues with sulfonylpiperazinyl motifs at position-7 were designed and synthesized. They were evaluated for in vitro cytotoxicity with the sulforhodamine-B (SRB) method in five types of human tumor cell lines, A-549, MDA-MB-231, KB, KB-VIN and MCF-7. With IC50 values in the low muM to nM level, most of the new analogues showed greater cytotoxicity activity than the reference compounds irinotecan and topotecan. Furthermore, compounds 12l (IC50, 1.2nM) and 12k (IC50, 20.2nM) displayed the highest cytotoxicity against the multidrug-resistant (MDR) KB-VIN cell line and merit further development as preclinical drug candidates for treating cancer, including MDR phenotype. Our study suggested that integration of sulfonylpiperazinyl motifs into position-7 of camptothecin is an effective strategy for discovering new potent cytotoxic camptothecin derivatives.

Keywords:

Methyl 7,15-dihydroxydehydroabietate,155205-65-5,Natural Products, buy Methyl 7,15-dihydroxydehydroabietate , Methyl 7,15-dihydroxydehydroabietate supplier , purchase Methyl 7,15-dihydroxydehydroabietate , Methyl 7,15-dihydroxydehydroabietate cost , Methyl 7,15-dihydroxydehydroabietate manufacturer , order Methyl 7,15-dihydroxydehydroabietate , high purity Methyl 7,15-dihydroxydehydroabietate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: